Therapeutic drug monitoring for invasive mould infections and disease: pharmacokinetic and pharmacodynamic considerations

Stott, Katharine E ORCID: 0000-0001-7079-7957 and Hope, William W ORCID: 0000-0001-6187-878X
(2017) Therapeutic drug monitoring for invasive mould infections and disease: pharmacokinetic and pharmacodynamic considerations. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 72 (suppl_). I12-I18.

[img] Text
Stott & Hope (revised) (9.11.16)_wh.docx - Author Accepted Manuscript

Download (67kB)


Therapeutic drug monitoring (TDM) may be required to achieve optimal clinical outcomes in the setting of significant pharmacokinetic variability, a situation that applies to a number of anti-mould therapies. The majority of patients receiving itraconazole should routinely be managed with TDM. Voriconazole exhibits highly variable inter-individual pharmacokinetics, and a trough concentration of 1.0-5.5 mg/L is widely accepted although it is derived from relatively low-quality evidence. The case for TDM of posaconazole is currently in a state of flux following the introduction of a newer tablet formulation with improved oral bioavailability, but it may be indicated when used for either prophylaxis or treatment of established disease. The novel broad-spectrum azole drug isavuconazole does not currently appear to require TDM but 'real-world' data are awaited and TDM could be considered in selected clinical cases. For both polyene and echinocandin agents, there are insufficient data regarding the relationship between serum concentrations and therapeutic outcomes to support the routine use of TDM. A number of practical challenges to the implementation of TDM in the treatment of invasive mould infections remain unsolved. The delivery of TDM as a future standard of care will require real-time measurement of drug concentrations at the bedside and algorithms for dosage adjustment. Finally, measures of pharmacodynamic effect are required to deliver therapy that is truly individualized.

Item Type: Article
Uncontrolled Keywords: Humans, Fungi, Nitriles, Triazoles, Itraconazole, Pyridines, Antifungal Agents, Drug Monitoring, Biological Availability, Voriconazole, Invasive Fungal Infections
Depositing User: Symplectic Admin
Date Deposited: 12 Feb 2018 08:38
Last Modified: 19 Jan 2023 07:06
DOI: 10.1093/jac/dkx029
Related URLs: